Adjusted EBITDA surged 19% despite IRA pricing headwinds and fuel cost pressures.

Why Guardian Pharmacy Services’ latest earnings matter for investors Guardian Pharmacy Services (GRDN) reported second quarter 2026 results on 6 August with higher net income versus a year earlier and updated full year guidance that points to higher expected revenue and adjusted EBITDA. Management linked the guidance change to underlying growth drivers, including mitigation of Inflation Reduction Act pricing pressures, recent acquisitions, new pharmacy openings, and a revised regional...

In the past week, Guardian Pharmacy Services, Inc. reported second-quarter 2026 results showing sales of US$351.77 million and net income of US$21.87 million, and it raised full-year 2026 revenue guidance to US$1.43 billion–US$1.45 billion while outlining ongoing expansion through acquisitions and new pharmacy openings. The combination of strong year-over-year profit growth, consistent earnings beats versus analyst estimates, and continued footprint expansion despite pricing pressure under...

Guardian Pharmacy Services (NYSE:GRDN) reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.

Guardian Pharmacy Services, Inc. (NYSE:GRDN) reported second-quarter 2026 results and increased its financial guidance for the full year, sending shares up around 3.

Guardian Pharmacy Services Inc (GRDN) boosts full-year outlook on 23% adjusted EBITDA growth while navigating IRA pricing pressures and maintaining a robust M&A pipeline.

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +11.54% and +3.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?